Madrigal Pharmaceuticals, Inc.

NasdaqGS MDGL

Madrigal Pharmaceuticals, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD -431.02 M

Madrigal Pharmaceuticals, Inc. Operating Cash Flow is USD -431.02 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -42.34% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

Madrigal Pharmaceuticals, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -302.81 M, a -41.24% change year over year.
Madrigal Pharmaceuticals, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -214.39 M, a -12.36% change year over year.
Madrigal Pharmaceuticals, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -190.81 M, a -66.07% change year over year.
Madrigal Pharmaceuticals, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -114.90 M, a -222.68% change year over year.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

NasdaqGS: MDGL

Madrigal Pharmaceuticals, Inc.

CEO	Mr. William J. Sibold
IPO Date	Feb. 6, 2007
Location	United States
Headquarters	Four Tower Bridge
Employees	376
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Key trends

Past 5 years